Spleen tyrosine kinase (SYK)

Spleen associated tyrosine kinase, commonly abbreviated as SYK, is a non-receptor tyrosine kinase with major roles in immune-cell signaling and inflammatory responses. It is widely studied as a therapeutic target because of its involvement in pathways that regulate activation of immune cells, cytokine production, and downstream inflammatory signaling. In biomedical research, SYK is often discussed in the context of diseases driven by immune dysregulation, including autoimmune disorders, inflammatory airway disease, ocular surface inflammation, hematologic malignancies, and other conditions in which aberrant signaling contributes to pathology.

As a drug target, SYK has attracted interest both as a standalone target and as part of dual-target strategies. Recent studies have evaluated SYK inhibitors in combination with other mechanisms, including HDAC inhibition in acute myeloid leukemia and VEGFR-2 inhibition in dry eye disease. These efforts reflect the broader therapeutic rationale for modulating SYK-mediated signaling to reduce inflammation or impair disease-promoting cellular programs.